Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

ROOT Brands® Addresses the GLP-1 Gap with CRUSH and SCULPT, a Science-Driven Protocol for Metabolic and Muscle Support After Ozempic® and Wegovy®

ROOT Brands® has introduced CRUSH™ and SCULPT™, a targeted nutritional protocol aimed at addressing the “GLP‑1 gap”—a growing concern among healthcare professionals and consumers regarding the metabolic and muscular support needs that GLP-1 receptor agonists like Ozempic® and Wegovy® do not fulfill. While these medications have revolutionized weight management through appetite suppression and blood sugar regulation, they do not provide the necessary support for maintaining lean muscle mass or metabolic efficiency after discontinuation. As the use of GLP-1 medications rises, so does the incidence of post-use challenges, including weight regain and low energy levels.

The clinical significance of CRUSH and SCULPT lies in their formulation, which targets the metabolic and cellular deficiencies that often emerge following GLP-1 therapy. CRUSH™ includes seven essential amino acids to enhance metabolic function and energy production, while SCULPT™ incorporates clinically validated ingredients such as InnoSlim® and Gymnema Sylvestre to support lean muscle and metabolic resilience. This dual approach addresses the common patterns observed post-GLP-1 use, where appetite and resting metabolic rates rebound, leading to rapid weight regain. By focusing on nutrient utilization and cellular health, these products aim to provide a comprehensive strategy for individuals transitioning off GLP-1 medications or seeking long-term metabolic support.

The introduction of CRUSH and SCULPT represents a paradigm shift in post-GLP-1 care, emphasizing the necessity for supportive nutritional strategies beyond pharmacological interventions. This innovation not only fills a critical gap in the weight management landscape but also highlights the importance of a holistic approach to health that prioritizes cellular-level wellness. As practitioners and researchers continue to explore the implications of GLP-1 therapies, the development of such targeted nutritional solutions could significantly influence future research and therapeutic strategies in metabolic health.

Source: globenewswire.com